Table 2

Comparison of clinical outcomes between P2Y12-receptor inhibitors

ClopidogrelvsticagrelorClopidogrelvsprasugrelTicagrelorvsprasugrel
Clopidogrel (n=1648)Ticagrelor
(n=811)
Clopidogrel (n=1648)Prasugrel
(n=1244)
Ticagrelor
(n=811)
Prasugrel
(n=1244)
30-day outcomes
 Mortality, n (%)
 Adjusted OR (95% CI)
117 (7.0)
1.00
56 (6.9)
1.05 (0.61 to 1.80)
117 (7.0)
1.00
40 (3.2)*
0.53 (0.34 to 0.85)*
56 (6.9)
1.00
40 (3.2)*
0.51 (0.29 to 0.91)*
 MI, n (%)
 Adjusted OR (95% CI)
48 (2.9)
1.00
9 (1.1)*
0.40 (0.17 to 0.94)*
48 (2.9)
1.00
21 (1.7)*
0.58 (0.32 to 1.05)
9 (1.1)
1.00
21 (1.7)
1.44 (0.61 to 3.42)
 Major bleeding, n (%)
 Adjusted OR (95% CI)
95 (6.1)
1.00
37 (4.6)
0.98 (0.64 to 1.52)
95 (6.1)
1.00
52 (4.6)
1.05 (0.73 to 1.52)
37 (4.6)
1.00
52 (4.6)
1.07 (0.67 to 1.70)
12-month outcomes
 Mortality, n (%)
 Adjusted OR (95% CI)
193 (11.7)
1.00
77 (9.5)
0.84 (0.55 to 1.29)
193 (11.7)
1.00
68 (5.5)*
0.55 (0.38 to 0.78)*
77 (9.5)
1.00
68 (5.5)*
0.65 (0.41 to 1.02)
 MI, n (%)
 Adjusted OR (95% CI)
108 (6.6)
1.00
26 (3.2)*
0.54 (0.32 to 0.93)*
108 (6.6)
1.00
47 (3.8)*
0.63 (0.42 to 0.94)*
26 (3.2)
1.00
47 (3.8)
1.16 (0.67 to 2.01)
  • Data are expressed in n (%).

  • *P value≤0.05.

  • MI, myocardial infarction.